December 04, 2017

Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research:

Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers

93 percent overall response rate in 17 pediatric patients with TRK fusion cancers / 94 percent of all patients remain on larotrectinib or received surgery with curative intent, four patients have been followed greater than one year and 12 have been followed greater than six months / Larotrectinib demonstrates central nervous system activity in first-ever TRK fusion glioblastoma response with a TRK inhibitor
Berlin, December 4, 2017 - Bayer and Loxo Oncology, Inc., a biopharmaceutical
company based in Stamford, Connecticut, US, (NASDAQ: LOXO), today announced
updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT
trial (NCT02637687). These data are being presented today at the American
Association for Cancer Research (AACR) Special Conference on Pediatric Cancer
Research in Atlanta, US. Bayer and Loxo Oncology are jointly developing
larotrectinib, an investigational compound being studied globally for the
treatment of patients with cancers harboring tropomyosin receptor kinase (TRK)
gene fusions, which are genetic alterations present across a wide range of
tumors resulting in uncontrolled TRK signaling and tumor growth.

"Targeted therapy success stories in pediatric oncology are uncommon, and
larotrectinib has invigorated the pediatric oncology community," said Brian
Turpin, D.O., the presenting SCOUT principal investigator and assistant
professor in the division of oncology at Cincinnati Children's Hospital.
"Larotrectinib's near universal response rate and compelling durability of
response in pediatric patients with TRK fusion cancers is likely to be practice
changing. Furthermore, the first-ever TRK inhibitor response in a TRK fusion
glioblastoma patient highlights the potential for larotrectinib in TRK fusion
central nervous system tumors."

"These data confirm that larotrectinib - a highly differentiated compound - can
deliver consistent and durable responses in TRK fusion patients across age
groups and multiple tumor types," said Robert LaCaze, Executive Vice President
and Head of the Oncology Strategic Business Unit at Bayer. We hope these data
continue to support future milestones that will ultimately improve outcomes and
change the course of cancer care for TRK fusion patients and their families."

As of the July 17, 2017 data cut-off date, 24 pediatric patients were enrolled,
including 17 patients with TRK fusion cancers. TRK fusion patients carried
primary diagnoses of infantile fibrosarcoma, thyroid cancer, and various soft
tissue sarcomas. The Overall Response Rate (ORR = PR + CR, Partial Response +
Complete Response) in the TRK fusion patients was 93 percent as assessed by
both the investigators and an independent review committee. Among the 17
patients with TRK fusion cancers, 94% either remain on drug or received surgery
with curative intent; four patients have been followed greater than one year
and 12 have been followed greater than six months. The larotrectinib adverse
event profile is consistent with data previously presented publicly. The most
common treatment-related adverse events at the dose given in the Phase II,
included increased liver function tests, neutropenia and nausea, all largely
grade 1.

These data are being presented in a poster session on December 4, 2017 and an
oral presentation on December 5, 2017. The poster and presentation will be
available online at https://www.loxooncology.com/focus/publications-abstracts
at the time of their scheduled presentations.

About Larotrectinib (LOXO-101)

Larotrectinib (LOXO-101) is a potent, oral and selective investigational new
drug in clinical development for the treatment of patients across a wide range
of cancers that harbor abnormalities involving the tropomyosin receptor kinases
(TRKs). Growing research suggests that the NTRK genes, which encode for TRKs,
can become abnormally fused to other genes, resulting in growth signals that
can lead to cancer in many sites of the body.

In an analysis of 55 adult and pediatric patients with TRK fusion cancers that
were evaluable according to RECIST, larotrectinib demonstrated a 75 percent
independently-reviewed confirmed overall response rate (ORR) and an 80 percent
investigator-assessed confirmed ORR, across many different types of solid
tumors. Larotrectinib received Orphan Drug Designation (ODD) in the US for the
treatment of solid tumors harboring NTRK-fusion proteins and in Europe for soft
tissue sarcoma. Additionally, the FDA granted breakthrough therapy designation
to larotrectinib for the treatment of unresectable or metastatic solid tumors
with NTRK-fusion proteins in adult and pediatric patients who require systemic
therapy and who have either progressed following prior treatment or who have no
acceptable alternative treatments.

For additional information about the larotrectinib or LOXO-195 clinical trials,
please refer to www.clinicaltrials.gov or visit www.loxooncologytrials.com.
Neither larotrectinib nor LOXO-195 are approved by the U.S. Food and Drug
Administration, the European Medicines Agency or any other health authority.

In November 2017, Bayer and Loxo Oncology entered into an exclusive global
collaboration on the development and commercialization of larotrectinib and
LOXO-195, a next-generation TRK inhibitor. Bayer and Loxo Oncology will jointly
develop the two products, larotrectinib and LOXO-195, and Bayer will lead
ex-U.S. regulatory activities as well as worldwide commercial activities. In
the U.S. Bayer and Loxo Oncology will co-promote the products. Loxo Oncology
will remain responsible for the filing in the U.S.

About TRK Fusion Cancer

TRK fusions are chromosomal abnormalities that occur when one of the NTRK genes
(NTRK1, NTRK2, NTRK3) becomes abnormally connected to another, unrelated gene
(e.g. ETV6, LMNA, TPM3). This abnormality results in uncontrolled TRK signaling
that can lead to cancer. TRK fusions occur rarely but broadly in various adult
and pediatric solid tumors, including appendiceal cancer, breast cancer,
cholangiocarcinoma, colorectal cancer, GIST, infantile fibrosarcoma, lung
cancer, mammary analogue secretory carcinoma of the salivary gland, melanoma,
pancreatic cancer, thyroid cancer, and various sarcomas. TRK fusions can be
identified through various diagnostic tests, including targeted next-generation
sequencing (NGS), immunohistochemistry (IHC), polymerase chain reaction (PCR),
and fluorescent in situ hybridization (FISH). For more information, please
visit www.TRKtesting.com.

Cancers Harboring Genetic Alterations
Scientists have long been working to better understand how a normal cell
becomes a cancer cell to deliver better therapies with fewer side effects. Some
people develop cancers that are caused by a single inappropriate DNA change,
known as "oncogenic drivers." When a genetic test identifies a patient with an
oncogenic driver, there is the potential for use of highly selective drugs that
inhibit oncogenic drivers in cancer. While there has been made notable progress
in improving outcomes for people living with cancer over the last several
decades, there has been a growing interest in developing highly targeted
medicines to treat cancer, to further maximize the patients' clinical benefit.
This development is supported by the increasing use of genetic testing in
cancer clinical medicine and improving chemistry approaches to building highly
selective inhibitors against single targets in the cancer cell.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a
portfolio of innovative treatments. The oncology franchise at Bayer includes
four marketed products and several other compounds in various stages of
clinical development. Together, these products reflect the company's approach
to research, which prioritizes targets and pathways with the potential to
impact the way that cancer is treated.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 99,600 people and had sales of EUR 34.9 billion. Capital
expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For
more information, go to www.bayer.com.

Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma
Find more information at www.pharma.bayer.com

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.